首页> 外文期刊>Colon & Rectum >Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial
【24h】

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial

机译:硫唑嘌呤与美沙拉嗪联合预防内镜复发克罗恩病患者的术后临床复发:一项随机,双盲,双模拟,多中心试验的疗效和安全性结果

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: The aim of the study was to compare azathioprine versus mesalazine tablets for the prevention of clinical recurrence in patients with postoperative Crohn's disease (CD) with moderate or severe endoscopic recurrence.Methods: This was a 1 year, double-blind, double-dummy, randomised study which took place in 21 gastroen-terology centres in Austria, the Czech Republic, Germany and Israel. The study participants were 78 adults with CD who had undergone resection with ileocolonic anastomosis in the preceding 6-24 months without subsequent clinical recurrence and with a Crohn's disease activity index (CDAI) score < 200, but with moderate or severe endoscopic recurrence. The study drugs were azathioprine 2.0-2.5 mg/kg/day or mesalazine 4 g/day over 1 year. The primary end point was therapeutic failure during 1 year, denned as a CDAI score > or = 200 and an increase of > or = 60 points from baseline, or study drug discontinuation due to lack of efficacy or intolerable adverse drug reaction.
机译:目的:本研究的目的是比较硫唑嘌呤与美沙拉嗪片在预防中度或重度内镜下复发克罗恩病(CD)患者的临床复发中的作用。方法:1年,双盲,双盲在奥地利,捷克共和国,德国和以色列的21个胃肠病学中心进行了虚拟的随机研究。该研究参与者为78例CD​​成年人,他们在之前的6-24个月内接受了回结肠结肠吻合术切除,无随后的临床复发,并且克罗恩病活动指数(CDAI)得分<200,但中度或重度内镜下复发。研究药物为1年内硫唑嘌呤2.0-2.5 mg / kg /天或美沙拉嗪4 g /天。主要终点是1年内的治疗失败,被定义为CDAI得分>或= 200,并且与基线相比增加了>或= 60点,或者由于缺乏疗效或无法忍受的不良药物反应而终止研究药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号